SAM
CPRX icon

Sawgrass Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Sawgrass Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,705
Closed -$230K – 193
2023
Q4 		$230K Sell
13,705
-38
-0.3% -$519 0.03% 185
2023
Q3 		$161K Sell
13,743
-2,601
-16% -$34.8K 0.02% 192
2023
Q2 		$220K Sell
16,344
-6,859
-30% -$98.7K 0.03% 171
2023
Q1 		$385K Buy
23,203
+417
+2% +$6.88K 0.05% 124
2022
Q4 		$424K Buy
22,786
+12,133
+114% +$187K 0.06% 118
2022
Q3 		$137K Sell
10,653
-4,535
-30% -$53.7K 0.02% 144
2022
Q2 		$106K Sell
15,188
-894
-6% -$6.56K 0.01% 151
2022
Q1 		$133K Buy
+16,082
New +$114K 0.01% 159
2021
Q4 		– Sell
-21,705
Closed -$115K – 204
2021
Q3 		$115K Sell
21,705
-1,485
-6% -$8.12K 0.01% 164
2021
Q2 		$133K Buy
+23,190
New +$120K 0.01% 177
2020
Q3 		– Sell
-10,870
Closed -$50K – 155
2020
Q2 		$50K Buy
+10,870
New +$48.8K ﹤0.01% 147

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sawgrass Asset Management's CPRX Position: Q1 2024 in Review

Sawgrass Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 13,705 shares — an estimated $230K sold.

Sawgrass Asset Management first reported a position in CPRX in Q2 2020 and held it in 11 quarters. The position peaked at $424K in Q4 2022. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Sawgrass Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Sawgrass Asset Management sold 13,705 Catalyst Pharmaceutical shares in Q1 2024, an estimated $230K.
  • Sawgrass Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2020 and held it in 11 quarters.
  • Sawgrass Asset Management's Catalyst Pharmaceutical position peaked at $424K in Q4 2022.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Sawgrass Asset Management's 13F filing for Q1 2024, filed 13 May 2024.